Spring Bank Pharmaceuticals Inc to Post FY2019 Earnings of ($1.67) Per Share, Jefferies Financial Group Forecasts (NASDAQ:SBPH)

Spring Bank Pharmaceuticals Inc (NASDAQ:SBPH) – Stock analysts at Jefferies Financial Group lifted their FY2019 earnings per share (EPS) estimates for shares of Spring Bank Pharmaceuticals in a research note issued to investors on Wednesday, January 29th. Jefferies Financial Group analyst M. Raycroft now anticipates that the company will earn ($1.67) per share for the year, up from their prior estimate of ($1.69). Jefferies Financial Group currently has a “Hold” rating and a $1.50 target price on the stock. Jefferies Financial Group also issued estimates for Spring Bank Pharmaceuticals’ Q4 2019 earnings at ($0.47) EPS, FY2020 earnings at ($0.82) EPS, FY2021 earnings at ($0.52) EPS, FY2022 earnings at ($0.83) EPS and FY2023 earnings at ($0.38) EPS.

Spring Bank Pharmaceuticals (NASDAQ:SBPH) last released its quarterly earnings results on Thursday, November 7th. The company reported ($0.42) EPS for the quarter, beating analysts’ consensus estimates of ($0.61) by $0.19.

Other equities research analysts have also issued reports about the company. Zacks Investment Research raised Spring Bank Pharmaceuticals from a “hold” rating to a “buy” rating and set a $1.50 target price for the company in a research report on Thursday, January 16th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Spring Bank Pharmaceuticals in a research report on Friday, December 20th. ValuEngine raised Spring Bank Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Friday, January 3rd. Piper Jaffray Companies decreased their target price on Spring Bank Pharmaceuticals from $10.00 to $1.70 in a research report on Monday, December 30th. Finally, B. Riley reaffirmed a “neutral” rating and set a $2.00 target price (down from $16.00) on shares of Spring Bank Pharmaceuticals in a research report on Monday, December 30th. Three research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. Spring Bank Pharmaceuticals presently has an average rating of “Buy” and a consensus target price of $10.12.

NASDAQ SBPH opened at $1.25 on Monday. The firm has a market capitalization of $20.60 million, a P/E ratio of -0.93 and a beta of 0.48. The business has a fifty day simple moving average of $2.13 and a 200 day simple moving average of $3.29. Spring Bank Pharmaceuticals has a 12 month low of $1.17 and a 12 month high of $11.21. The company has a current ratio of 12.18, a quick ratio of 12.18 and a debt-to-equity ratio of 0.52.

Institutional investors have recently made changes to their positions in the company. Millennium Management LLC increased its position in shares of Spring Bank Pharmaceuticals by 21.1% during the 3rd quarter. Millennium Management LLC now owns 100,077 shares of the company’s stock valued at $350,000 after purchasing an additional 17,465 shares during the last quarter. Morse Asset Management Inc increased its position in shares of Spring Bank Pharmaceuticals by 256.8% during the 3rd quarter. Morse Asset Management Inc now owns 42,935 shares of the company’s stock valued at $148,000 after purchasing an additional 30,900 shares during the last quarter. Hikari Power Ltd increased its position in shares of Spring Bank Pharmaceuticals by 162.3% during the 3rd quarter. Hikari Power Ltd now owns 160,914 shares of the company’s stock valued at $554,000 after purchasing an additional 99,578 shares during the last quarter. Morgan Stanley increased its position in shares of Spring Bank Pharmaceuticals by 102.7% during the 2nd quarter. Morgan Stanley now owns 44,963 shares of the company’s stock valued at $166,000 after purchasing an additional 22,776 shares during the last quarter. Finally, Jane Street Group LLC purchased a new stake in Spring Bank Pharmaceuticals in the 2nd quarter worth about $59,000. 39.14% of the stock is owned by hedge funds and other institutional investors.

About Spring Bank Pharmaceuticals

Spring Bank Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers and develops therapeutics for the treatment of viral infections, inflammatory diseases, and various cancers using small molecule nucleotide platform. Its lead product candidate is inarigivir soproxil for the treatment of chronic hepatitis B virus (HBV).

Recommended Story: What is Liquidity?

Earnings History and Estimates for Spring Bank Pharmaceuticals (NASDAQ:SBPH)

Receive News & Ratings for Spring Bank Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spring Bank Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.